Cleveland Clinic's 2020 Management of Checkpoint Inhibitor-Related Toxicity
Endocrine Complications of IO: Pituitary Hormone Profile Should Be Appropriately Monitored for Pts on Anti-CTLA-4, Primary Thyroid Dysfunction Is More Frequently Observed in Anti-PD-1/PDL-1 Therapy
Comments 0
Login to view comments.
Click here to Login
